In the last 12 months, insiders at Sagimet Biosciences Inc. ($SGMT) filed 65 transactions with the SEC: 1 open-market purchases totaling $63,731 and 12 sales totaling $1,345,811. Net insider sentiment: net selling.
Sagimet Biosciences Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Happel David (President & CEO) — 7 transactions totaling $726,711
- Kemble George (Executive Chairman) — 3 transactions totaling $408,414
- Rozek Elizabeth (General Counsel and CCO) — 4 transactions totaling $132,301
- Martins Eduardo Bruno (Chief Medical Officer) — 7 transactions totaling $121,028
- Rozek Elizabeth (Chief Legal & Admin. Officer) — 5 transactions totaling $14,054
View all SEC Filings for Sagimet Biosciences Inc. (SGMT).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | A | Series A Common Stock | 44000 | $0.00 | 234,959.0000 | 32,464,893 | 23.04% | 0.14% |
| Feb. 19, 2026 | Chauche Thierry | Chief Financial Officer | A | Stock Option (Right to Buy) | 88000 | $0.00 | 88,000.0000 | 32,464,893 | 9999.99% | 0.27% |
| Feb. 19, 2026 | Chauche Thierry | Chief Financial Officer | A | Series A Common Stock | 44000 | $0.00 | 59,688.0000 | 32,464,893 | 280.47% | 0.14% |
| Feb. 19, 2026 | Happel David | President & CEO | A | Stock Option (Right to Buy) | 256000 | $0.00 | 256,000.0000 | 32,464,893 | 9999.99% | 0.79% |
| Feb. 19, 2026 | Happel David | President & CEO | A | Series A Common Stock | 128000 | $0.00 | 805,621.0000 | 32,464,893 | 18.89% | 0.39% |
| Feb. 19, 2026 | Martins Eduardo Bruno | Chief Medical Officer | A | Stock Option (Right to Buy) | 88000 | $0.00 | 88,000.0000 | 32,464,893 | 9999.99% | 0.27% |
| Feb. 19, 2026 | Martins Eduardo Bruno | Chief Medical Officer | A | Series A Common Stock | 44000 | $0.00 | 147,296.0000 | 32,464,893 | 42.60% | 0.14% |
| Feb. 19, 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | A | Stock Option (Right to Buy) | 88000 | $0.00 | 88,000.0000 | 32,464,893 | 9999.99% | 0.27% |
| Feb. 10, 2026 | Chauche Thierry | Chief Financial Officer | S | Series A Common Stock | 1312 | $5.36 | 15,688.0000 | 32,464,893 | 7.72% | 0.00% |
| Feb. 10, 2026 | Happel David | President & CEO | S | Series A Common Stock | 12101 | $5.36 | 677,621.0000 | 32,464,893 | 1.75% | 0.04% |
| Feb. 10, 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | S | Series A Common Stock | 2622 | $5.36 | 190,959.0000 | 32,464,893 | 1.35% | 0.01% |
| Feb. 10, 2026 | Martins Eduardo Bruno | Chief Medical Officer | S | Series A Common Stock | 3640 | $5.36 | 103,296.0000 | 32,464,893 | 3.40% | 0.01% |
| Nov. 20, 2025 | Kemble George | Executive Chairman | S | Series A Common Stock | 37688 | $7.69 | 81,005.0000 | 32,464,893 | 31.75% | 0.12% |
| Nov. 4, 2025 | Rozek Elizabeth | Chief Legal & Admin. Officer | A | Series A Common Stock | 9855 | $0.00 | 193,581.0000 | 32,464,893 | 5.36% | 0.03% |
| Nov. 4, 2025 | Rozek Elizabeth | Chief Legal & Admin. Officer | A | Stock Option (Right to Buy) | 13367 | $0.00 | 13,367.0000 | 32,464,893 | 9999.99% | 0.04% |
| July 21, 2025 | Rozek Elizabeth | General Counsel and CCO | S | Series A Common Stock | 10780 | $9.13 | 183,726.0000 | 32,195,366 | 5.54% | 0.03% |
| July 21, 2025 | Happel David | President & CEO | S | Series A Common Stock | 65478 | $9.13 | 689,722.0000 | 32,195,366 | 8.67% | 0.20% |
| July 21, 2025 | Martins Eduardo Bruno | Chief Medical Officer | S | Series A Common Stock | 8277 | $9.13 | 106,936.0000 | 32,195,366 | 7.18% | 0.03% |
| June 9, 2025 | Jarrett Jennifer | Director | A | Stock Option (Right to Buy) | 27268 | $0.00 | 27,268.0000 | 32,195,345 | 9999.99% | 0.08% |
| June 9, 2025 | Walbert Timothy P | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| June 6, 2025 | SEIDENBERG BETH C | Director | A | Stock Option (Right to Buy) | 28522 | $0.00 | 28,522.0000 | 32,195,345 | 9999.99% | 0.09% |
| June 9, 2025 | SEIDENBERG BETH C | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| June 9, 2025 | Phillips Anne M. | Director | A | Stock Option (Right to Buy) | 27268 | $0.00 | 27,268.0000 | 32,195,345 | 9999.99% | 0.08% |
| June 9, 2025 | Kemble George | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| June 9, 2025 | Hoelscher Paul W. | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| June 9, 2025 | GRAMMER ELIZABETH A | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| Feb. 6, 2025 | Rozek Elizabeth | General Counsel and CCO | A | Series A Common Stock | 34000 | $0.00 | 194,506.0000 | 31,350,725 | 21.18% | 0.11% |
| Feb. 6, 2025 | Chauche Thierry | Chief Financial Officer | A | Stock Option (Right to Buy) | 69000 | $0.00 | 69,000.0000 | 31,350,725 | 9999.99% | 0.22% |
| Feb. 6, 2025 | Chauche Thierry | Chief Financial Officer | A | Series A Common Stock | 17000 | $0.00 | 17,000.0000 | 31,350,725 | 9999.99% | 0.05% |
| Feb. 6, 2025 | Rozek Elizabeth | General Counsel and CCO | A | Stock Option (Right to Buy) | 138000 | $0.00 | 138,000.0000 | 31,350,725 | 9999.99% | 0.44% |
| Feb. 6, 2025 | Martins Eduardo Bruno | Chief Medical Officer | A | Series A Common Stock | 34000 | $0.00 | 115,213.0000 | 31,350,725 | 41.87% | 0.11% |
| Feb. 6, 2025 | Martins Eduardo Bruno | Chief Medical Officer | A | Stock Option (Right to Buy) | 138000 | $0.00 | 138,000.0000 | 31,350,725 | 9999.99% | 0.44% |
| Feb. 6, 2025 | Happel David | President & CEO | A | Series A Common Stock | 116000 | $0.00 | 755,200.0000 | 31,350,725 | 18.15% | 0.37% |
| Feb. 6, 2025 | Happel David | President & CEO | A | Stock Option (Right to Buy) | 472000 | $0.00 | 472,000.0000 | 31,350,725 | 9999.99% | 1.51% |
| Aug. 1, 2024 | Phillips Anne M. | Director | A | Stock Option (Right to Buy) | 113895 | $0.00 | 113,895.0000 | 31,913,887 | 9999.99% | 0.36% |
| Aug. 1, 2024 | Jarrett Jennifer | Director | A | Stock Option (Right to Buy) | 113895 | $0.00 | 113,895.0000 | 31,913,887 | 9999.99% | 0.36% |
| July 23, 2024 | Kemble George | Executive Chairman | S | Series A Common Stock | 23625 | $3.17 | 118,693.0000 | 31,913,887 | 16.60% | 0.07% |
| July 19, 2024 | Rozek Elizabeth | General Counsel and CCO | S | Series A Common Stock | 10914 | $3.10 | 160,506.0000 | 31,913,887 | 6.37% | 0.03% |
| July 19, 2024 | Martins Eduardo Bruno | Chief Medical Officer | S | Series A Common Stock | 8357 | $3.10 | 81,213.0000 | 31,913,887 | 9.33% | 0.03% |
| July 19, 2024 | Kemble George | Executive Chairman | S | Series A Common Stock | 14062 | $3.10 | 142,318.0000 | 31,913,887 | 8.99% | 0.04% |
| June 5, 2024 | SEIDENBERG BETH C | Director | A | Stock Option (Right to Buy) | 51459 | $0.00 | 51,459.0000 | 29,039,427 | 9999.99% | 0.18% |
| June 5, 2024 | Parsey Merdad | Director | A | Stock Option (Right to Buy) | 51459 | $0.00 | 51,459.0000 | 29,039,427 | 9999.99% | 0.18% |
| June 5, 2024 | Hoelscher Paul W. | Director | A | Stock Option (Right to Buy) | 9279 | $0.00 | 9,279.0000 | 29,039,427 | 9999.99% | 0.03% |
| June 5, 2024 | GRAMMER ELIZABETH A | Director | A | Stock Option (Right to Buy) | 51459 | $0.00 | 51,459.0000 | 29,039,427 | 9999.99% | 0.18% |
| June 5, 2024 | Walbert Timothy P | Director | A | Stock Option (Right to Buy) | 9279 | $0.00 | 9,279.0000 | 29,039,427 | 9999.99% | 0.03% |
| May 6, 2024 | Chauche Thierry | Chief Financial Officer | A | Stock Option (Right to Buy) | 587181 | $0.00 | 587,181.0000 | 29,039,427 | 9999.99% | 2.02% |
| April 1, 2024 | Hoelscher Paul W. | Director | A | Stock Option (Right to Buy) | 73014 | $0.00 | 73,014.0000 | 29,039,427 | 9999.99% | 0.25% |
| April 1, 2024 | Walbert Timothy P | Director | A | Stock Option (Right to Buy) | 73014 | $0.00 | 73,014.0000 | 29,039,427 | 9999.99% | 0.25% |
| March 26, 2024 | Happel David | President & CEO | P | Series A Common Stock | 12100 | $5.27 | 639,200.0000 | 10,460,335 | 1.93% | 0.12% |
| Jan. 29, 2024 | NEW ENTERPRISE ASSOCIATES 13 LP | TenPercentOwner | J | Series A Common Stock | 850000 | $0.00 | 3,000,275.0000 | 10,460,335 | 22.08% | 8.13% |
| Jan. 29, 2024 | BASKETT FOREST | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,272,525.0000 | 10,460,335 | 8.66% | 2.49% |
| Jan. 29, 2024 | BASKETT FOREST | TenPercentOwner | J | Series A Common Stock | 850000 | $0.00 | 3,011,575.0000 | 10,460,335 | 22.01% | 8.13% |
| Jan. 29, 2024 | KERINS PATRICK J | TenPercentOwner | J | Series A Common Stock | 13139 | $0.00 | 3,013,414.0000 | 10,460,335 | 0.44% | 0.13% |
| Jan. 29, 2024 | KERINS PATRICK J | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,013,414.0000 | 10,460,335 | 7.97% | 2.49% |
| Jan. 29, 2024 | KERINS PATRICK J | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,274,364.0000 | 10,460,335 | 8.66% | 2.49% |
| Jan. 29, 2024 | KERINS PATRICK J | TenPercentOwner | J | Series A Common Stock | 850000 | $0.00 | 3,013,414.0000 | 10,460,335 | 22.00% | 8.13% |
| Jan. 29, 2024 | SANDELL SCOTT D | TenPercentOwner | J | Series A Common Stock | 6997 | $0.00 | 3,007,272.0000 | 10,460,335 | 0.23% | 0.07% |
| Jan. 29, 2024 | SANDELL SCOTT D | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,007,272.0000 | 10,460,335 | 7.98% | 2.49% |
| Jan. 29, 2024 | SANDELL SCOTT D | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,268,222.0000 | 10,460,335 | 8.68% | 2.49% |
| Jan. 29, 2024 | SANDELL SCOTT D | TenPercentOwner | J | Series A Common Stock | 850000 | $0.00 | 3,007,272.0000 | 10,460,335 | 22.04% | 8.13% |
| Jan. 29, 2024 | BASKETT FOREST | TenPercentOwner | J | Series A Common Stock | 11300 | $0.00 | 3,011,575.0000 | 10,460,335 | 0.38% | 0.11% |
| Jan. 29, 2024 | BASKETT FOREST | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,011,575.0000 | 10,460,335 | 7.97% | 2.49% |
| Jan. 29, 2024 | NEA Partners 13, Limited Partnership | TenPercentOwner | J | Series A Common Stock | 850000 | $0.00 | 3,000,275.0000 | 10,460,335 | 22.08% | 8.13% |
| Jan. 29, 2024 | NEA Partners 13, Limited Partnership | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,261,225.0000 | 10,460,335 | 8.70% | 2.49% |
| Jan. 29, 2024 | NEA Partners 13, Limited Partnership | TenPercentOwner | J | Series A Common Stock | 260950 | $0.00 | 3,000,275.0000 | 10,460,335 | 8.00% | 2.49% |